Glenn Schexnayder, MD
Family Medicine · Donaldsonville, LANPI 1841280633
Payments from drug & device makers
Across 638 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$767
- Novo Nordisk$621
- Johnson & Johnson$481
- Bayer$443
- plus $5K from 29 others
What the payments were for
- Food & beverage$11,045100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 166 | $2,263 |
| Lilly USA, LLC | 74 | $1,279 |
| Boehringer Ingelheim | 44 | $767 |
| Novo Nordisk | 32 | $621 |
| Johnson & Johnson | 29 | $481 |
| Bayer | 28 | $443 |
| Amgen | 23 | $437 |
| Pfizer | 26 | $420 |
| Abbott | 9 | $403 |
| AstraZeneca(2 entities) | 22 | $393 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $373 |
| Axsome Therapeutics, Inc. | 11 | $329 |
| Amarin Pharma, Inc. | 11 | $304 |
| Otsuka America Pharmaceutical, Inc. | 12 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $256 |
| Merck | 10 | $207 |
| GSK | 10 | $188 |
| Esperion Therapeutics, Inc. | 11 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $182 |
| Ironwood Pharmaceuticals, Inc | 8 | $172 |
| Novartis | 9 | $161 |
| Ardelyx, Inc. | 5 | $143 |
| Sanofi-aventis U.S. LLC | 10 | $141 |
| Exact Sciences | 7 | $129 |
| Corium, LLC | 8 | $126 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 3 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Eisai Inc. | 2 | $26 |
| Biogen | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $14 |
| Renalytix AI, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,059 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 331 | $362,766 |
| JardianceEmpagliflozin | 195 | $199,151 |
| OzempicSemaglutide | 92 | $96,452 |
| LinzessLinaclotide | 100 | $93,323 |
| EliquisApixaban | 70 | $68,168 |
| FarxigaDapagliflozin Propanediol | 65 | $62,104 |
| InvokanaCanagliflozin | 52 | $57,696 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $37,278 |
| JanuviaSitagliptin Phosphate | 27 | $37,218 |
| TrulicityDulaglutide | 23 | $35,509 |
| MyrbetriqMirabegron | 29 | $26,516 |
| XareltoRivaroxaban | 25 | $22,209 |
| VascepaIcosapent Ethyl | 40 | $21,642 |
| Repatha SureclickEvolocumab | 18 | $19,966 |
| VraylarCariprazine Hcl | 14 | $18,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,279 | $398,275354 claims |
| Boehringer IngelheimJardiance | $767 | $199,151195 claims |
| AbbVieLinzess, Vraylar, Synthroid | $2,263 | $114,161140 claims |
| Novo NordiskOzempic | $621 | $96,45292 claims |
| Johnson & JohnsonInvokana, Xarelto, Invokamet | $481 | $86,23188 claims |
| PfizerEliquis | $420 | $68,16870 claims |
| AstraZenecaFarxiga | $393 | $62,10465 claims |
| MerckJanuvia, Belsomra | $207 | $42,29339 claims |
| GSKTrelegy Ellipta | $188 | $37,27859 claims |
| Esperion Therapeutics, Inc.Nexletol | $182 | $17,67424 claims |
| BayerKerendia | $443 | $14,54019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Donaldsonville
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.